13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations
- 1 April 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 31 (4), 392-399
- https://doi.org/10.1097/inf.0b013e31824b972b
Abstract
Background: As multiple vaccines are administered concomitantly during routine pediatric immunizations, it is important to ascertain the potential interference of any new vaccine on the immune response to the concomitantly administered vaccines. Immune responses to meningococcal serogroup C-tetanus toxoid conjugate vaccine (MnCC-TT) and the diphtheria and tetanus antigens in routine pediatric vaccines (diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated poliovirus/Haemophilus influenza type b [DTaP-HBV-IPV/Hib] and DTaP-IPV+Hib) when given concomitantly with the 13-valent pneumococcal conjugate vaccine (PCV13) were compared with responses when given with PCV7. In addition, the immunogenicity and safety of PCV13 were assessed. Methods: Healthy infants were randomized to receive PCV13 or PCV7 (ages 2, 4, 6 and 15 months), concomitant with MnCC-TT (2, 4 and 15 months), DTaP-HBV-IPV/Hib (2, 4 and 6 months), and DTaP-IPV+Hib (15 months). Results: Immune responses to MnCC-TT and to the diphtheria and tetanus antigens administered with PCV13 were noninferior to the responses observed when the vaccines were administered with PCV7; >= 96.6 (postinfant) and >= 99.4% (posttoddler) subjects achieved prespecified immune response levels to each antigen in each group. After the infant series, >= 93.0% of subjects receiving PCV13 achieved pneumococcal anticapsular immunoglobulin G concentrations >= 0.35 mu g/mL for all serotypes except serotype 3 (86.2%), increasing to 98.1-100% for most serotypes (serotype 3: 93.6%) after the toddler dose. Local and systemic reactions were similar between groups. Conclusions: Immune responses to MnCC-TT, and other childhood vaccines (DTaP-HBV-IPV/Hib, DTaP-IPV+Hib) were noninferior when concomitantly administered with PCV13 compared with PCV7. PCV13 does not interfere with MnCC-TT. PCV13 is highly immunogenic with a favorable safety profile.Keywords
This publication has 28 references indexed in Scilit:
- Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in CanadaThe Pediatric Infectious Disease Journal, 2012
- Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccineVaccine, 2011
- Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccinesVaccine, 2010
- Effectiveness of Pneumococcal Conjugate Vaccine Using a 2+1 Infant Schedule in Quebec, CanadaThe Pediatric Infectious Disease Journal, 2010
- Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and ToddlersClinical and Vaccine Immunology, 2010
- Susceptibility of Recently Collected Spanish Pneumococci Nonsusceptible to Oral Penicillin from Serotypes Not Included in the 7-Valent Conjugate VaccineAntimicrobial Agents and Chemotherapy, 2010
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Universal childhood immunisation against Streptococcus pneumoniae: The five-year experience of Liguria Region, ItalyVaccine, 2009
- Calendario vacunal de la Asociación Española de Pediatría: Recomendaciones 2009Anales de Pediatría, 2009
- Assignment of Weight-Based Antibody Units for 13 Serotypes to a Human Antipneumococcal Standard Reference Serum, Lot 89-S(F)Clinical and Vaccine Immunology, 2004